homepage-top-section

The drug is claimed to be the first and only oral MET inhibitor recommended to treat advanced NSCLC harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping

Padcev is indicated as a monotherapy to treat locally advanced or metastatic urothelial cancer adult patients who previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The regulatory

Led by Deerfield Management, the funding round saw participation from existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform backed by KKR,

HBM7022 has been produced from HBM’s HCAb Based Immune Cell Engagers (HBICE) Platform. It crosslinks tumour and T cells by targeting a tumour-associated antigen (Claudin18.2) and CD3 that

This agreement is on developing and commercialising a gene therapy product based on ViGeneron’s engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD). As

A recombinant humanized IgG4 monoclonal antibody, TAB009/JS009 is developed against human CD112R to treat advanced malignant tumours. CD112R, also known as Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), is

Under the deal, Organon will obtain global rights to FDA-approved Xaciato, which is intended to treat bacterial vaginosis (BV) in females aged 12 years and above. The vaginal

The company filed the NDA with the Department of Health in the Hong Kong Special Administrative Region. The SG drug is a first-in-class Trop-2 directed antibody-drug conjugate and

The first-in-class bio-HDL mimetic CER-001 works by directly targeting a key underlying metabolic defect of LCAT deficiency. Its anti-inflammatory properties and/or the increase in the Reverse Cholesterol Transport